SAGE - Sage stock rises 15% as drug shows function/learning benefit in Alzheimer's patients with dementia

Sage Therapeutics (NASDAQ:SAGE) said a mid-stage study of SAGE-718 showed improvement on multiple tests of executive performance and learning and memory in patients with mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD). In the phase 2 trial, dubbed LUMINARY, several tests were used to assess multiple domains of cognitive performance in 26 patients, aged 50–80 years, receiving SAGE-718 3-mg once daily for 14 days. The company said that at day 14, improvements from the time treatment started were seen on tests of executive functioning (digit symbol substitution, multitasking, one touch stockings, spatial working memory, and 2-Back tests) and tests on learning and memory (pattern recognition memory and verbal recognition memory tests). The company added statistically significant improvement, according to a cognitive assessment test was seen at Day 28. Sage, however, noted that no appreciable effect was seen on measures of simple attention/psychomotor speed, which was keeping with the profile of

For further details see:

Sage stock rises 15% as drug shows function/learning benefit in Alzheimer’s patients with dementia